pH-responsive molecular nanocarriers based on dendritic core-shell architectures.

Michael Krämer; Jean-François Stumbé; Holger Türk; Simon Krause; Ansgar Komp; Lydie Delineau; Svetlana Prokhorova; Holger Kautz; Rainer Haag

doi:10.1002/1521-3773(20021115)41:22<4252::aid-anie4252>3.0.co;2-f

PubMed · 12434354

pH-responsive molecular nanocarriers based on dendritic core-shell architectures.

Michael Krämer·Jean-François Stumbé·Holger Türk·Simon Krause·Ansgar Komp·Lydie Delineau·Svetlana Prokhorova·Holger Kautz·Rainer Haag

View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Aziridines Congo Red Drug Carriers Drug Stability Glycerol Hydrogen-Ion Concentration Microscopy, Atomic Force Nanotechnology Polymers Spectrophotometry, Infrared Structure-Activity Relationship Time Factors Water Journal Article Research Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Michael Krämer, Jean-François Stumbé, Holger Türk, Simon Krause, Ansgar Komp, Lydie Delineau, Svetlana Prokhorova, Holger Kautz, Rainer Haag. 2002-11-15. pH-responsive molecular nanocarriers based on dendritic core-shell architectures.. https://doi.org/10.1002/1521-3773(20021115)41%3A22%3C4252%3A%3Aaid-anie4252%3E3.0.co%3B2-f

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Unveiling Aziridine-Containing Natural Products by Genomic and Spectroscopic Approaches.

Aziridine-containing natural products are prized for their potent bioactivities, yet their scarcity and poorly understood biosynthesis have limited systematic exploration. Here, we address this by integrating genome mining with a 1H-13C coupled HSQC metabolomic approach that exploits the distinctive NMR signatures of aziridines, enabling their direct detection from complex extracts. This strategy unveiled the desertolides, the first macrolides incorporating a rare terminal 2-methyl-aziridine-2-carboxylate moiety. Genetic and isotopic studies identified a dedicated biosynthetic subcluster (desA-desN) that assembles and installs this unit from glutamate, and heterologous expression confirmed the self-sufficiency of this subcluster. Direct MS evidence reveals the aziridine moiety covalently bound to the active-site Cys113 of DesN, establishing this KAS III homolog as the first dedicated aziridine-transferase and a promising tool for polyketide engineering. Bioinformatic analysis uncovered over 50 biosynthetic gene clusters, suggesting that this aziridine-associated biosynthetic logic may be more widespread than currently appreciated. This work establishes a tractable platform for the targeted discovery and engineered biosynthesis of aziridine-containing natural products, opening this underexplored pharmacophore to systematic interrogation.

Aziridines↗

PubMed2007

Reducible poly(amido ethylenimine) directed to enhance RNA interference.

Designing synthetic macromolecular vehicles with high transfection efficiency and low cytotoxicity has been a major interest in the development of non-viral gene carriers. A reducible poly(amido ethylenimine) (SS-PAEI) synthesized by addition copolymerization of triethylenetetramine and cystamine bis-acrylamide (poly(TETA/CBA)) was used as a carrier for small interference RNA (siRNA). Poly(TETA/CBA) could efficiently condense siRNA to form stable complexes under physiological conditions and perform complete release of siRNA in a reductive environment. When formulated with VEGF-directed siRNA, poly(TETA/CBA) demonstrated significantly higher suppression of VEGF than linear-polyethylenimine (PEI) (L-PEI, 25kDa) in human prostate cancer cells (PC-3). After 5h of transfection, substantial dissociation and intracellular distribution of siRNA was observed in the poly(TETA/CBA) formulation, but not in the L-PEI formulation. The triggered release of siRNA by reductive degradation of poly(TETA/CBA) in the cytoplasm may affect the RNAi activity by increasing cytoplasmic availability of siRNA. These results suggest that the rational design of non-viral carriers should involve considerations for intracellular dissociation and trafficking of a nucleic acid drug to maximize its effect, in conjunction with formation of stable complexes under physiological conditions.

Aziridines↗

PubMed2007

Synthesis of beta-lactam scaffolds for ditopic peptidomimetics.

[reaction: see text] Ring opening of alpha-substituted-alpha-methoxycarbonyl-N-nosylaziridines provides a practical access to enantiopure alpha,alpha'-disubstituted beta-lactam scaffolds, novel types of ditopic reverse turn surrogates. The procedure is general, short, and high yielding and starts from handy alpha-substituted serinates and alpha-amino acid derivatives.

Aziridines↗